Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis
- 271 Downloads
Background and aims
While the association between platelet activation and hepatic fibrosis has been previously demonstrated in animal studies; the utility of anti-platelet agents in reversing the progression of hepatic fibrosis requires further review. Utilizing systematic review methods, we provide to our knowledge the first meta-analysis combining evidence from all studies aimed to establish the effect of anti-platelet agents in the prevention of hepatic fibrosis.
We searched Medline, EMBASE and PubMed databases from inception to October 2018 to identify all studies aimed at evaluating the role of anti-platelet agents in the prevention of hepatic fibrosis. The primary outcome was hepatic fibrosis. The initial title, abstract, and full-text screening were performed in duplicate. Risk of bias was evaluated using the Newcastle–Ottawa Scale. A fixed-effect generic inverse variance method was used to create a pooled estimate of the odds of hepatic fibrosis in patients with anti-platelet agents versus without anti-platelet agents.
Among the 2310 unique articles identified during the title screening, 4 studies with a combined population of 3141 patients were deemed eligible for inclusion into the meta-analysis establishing the effect of anti-platelet agents on hepatic fibrosis. One study failed to report their findings in the entire cohort, electing to instead summarize the effects of anti-platelets within subgroups categorized by fibrotic risk factors. Use of anti-platelets was associated with 32% decreased odds of hepatic fibrosis, (adjusted pooled OR 0.68; CI 0.56–0.82, p ≤ 0.0001). The statistical heterogeneity among the studies was insignificant.
Use of anti-platelet agents is associated with the decreased odds of hepatic fibrosis. Due to limited evidence, future high-quality randomized controlled trials with larger comparative samples are required to further delineate the potential beneficial effects of these drugs in preventing hepatic fibrosis.
KeywordsHepatic fibrosis Aspirin Anti-platelets Systematic review
UI: study design, literature searching, data abstraction and manuscript writing, statistical analysis. BBD: manuscript writing and drafting the tables. AAL: study design, manuscript writing. GC: study design and manuscript writing. DK: study design, literature review and manuscript writing and reviewing. MAK: study design, literature review and manuscript writing and reviewing. AA: study design, literature search and review. Manuscript writing and finalizing.
There were no funding sources for this study.
Compliance with ethical standards
Conflict of interest
Umair Iqbal, Brittany B. Dennis, Andrew A. Li, George Cholankeril, Donghee Kim, Muhammad Ali Khan and Aijaz Ahmed declare no conflict of interest, including financial and/or material support for the preparation of this manuscript.
- 6.Denda A, Tang Q, Endoh T, et al. Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, l-Amino acid-defined diet in rats. Carcinogenesis 1994;15(6):1279–1283CrossRefPubMedGoogle Scholar
- 21.Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol 2017;112(10):1495–505CrossRefPubMedGoogle Scholar